Home
HitGen

HitGen Market Share Analysis for August 2026

hitgen focuses on the development of new drugs and is committed to creating the world's best quality dna encoded library with independent intellectual property rights as a "new engine" for the creation of new drugs.

Health > Biotechnology and Pharmaceuticals

Domainhitgen.com

Year Founded2012

Employees201 - 500

Annual Revenue$5M - $10M

HitGen

HitGen (including company regionals)

hitgen.com

See more website traffic and engagement information

HitGen Revenue up to August 2026 is 5M - 10M

revenue generated by HitGen top domains

HitGen top domains revenue over 3 years

Revenue for HitGen top domains

hitgen.com5M - 10M

See more with Sales Intelligence

Total visits to HitGen's top domains

Understand HitGen market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

hitgen.com5.2K

See more with Sales Intelligence

Avg. visit duration in HitGen's top domains

Analyze HitGen engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

hitgen.com00:00:14

See more with Sales Intelligence

Avg. pageviews on HitGen's top domains

See how HitGen keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

hitgen.com1.78

See more with Sales Intelligence

HitGen top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by HitGen

These are the website technologies, by industry, used by HitGen top domains

Advertising (6)

DoubleClick

Widget (3)

General Captcha

Conversion & Analytics (2)

Google Analytics

Content Management System (1)

WordPress

More Technologies

4

See all

News & Signals from HitGen

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHitGen Ltd partnered with BioAge on Apr 1st '21.The collaboration between HitGen and BioAge has previously resulted in the successful identification of promising hit molecules announced in April 2021, a joint publication in Bioorganic & Medicinal Chemistry Letters in February 2024 entitled "The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening", and joint patent filings covering the structurally novel compounds discovered through the DEL screening process.

NewsMission BioCapital LP partnered with HitGen Ltd on Apr 2nd '26.Mission BioCapital also announced today the following nine winners of the 2025 Mission BioCapital Platinum Program, investing a total of $4 million and providing incubator space and mentorship, in partnership with Eli Lilly and Company, OVI, Alloy Therapeutics, HitGen, Goodwin, and van den Boom & Associates:

NewsHitGen Ltd launches OpenDEL 5.0.Advancing DEL technology for the research lab: HitGen introduces OpenDEL(TM) 5.0.